Therapeutic effect of vitamin d supplementation in a pilot study of crohn's patients

Clinical and Translational Gastroenterology

Volumn 4, Issue , 2013, Pages

  Yang, Linlin ^a   Weaver, Veronika ^a   Smith, Jill P ^b   Bingaman, Sandra ^b   Hartman, Terryl J ^c   Cantorna, Margherita T ^a  

^a Center for Molecular Immunology and Infectious Disease   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINOSALICYLIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIFEDIOL; CALCIUM; COLECALCIFEROL; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 17; OPIATE ANTAGONIST; PARATHYROID HORMONE; PURINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INFECTION; MALE; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RASH; SCORING SYSTEM; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

EID: 84885743052     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2013.1     Document Type: Article

References (24)

1. Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis 2009; 15: 128-133
2. Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J Gastroenterol 2008; 14: 165-173
3. Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. Clin Sci 2004; 107: 331-341
4. DeLuca HF. Vitamin D. Nutrition Today 1993; 28: 6-11
5. Clemens TL, Adams JS, Nolan JM et al. Measurement of circulating vitamin D in man. Clin Chim Acta 1982; 121: 301-308
6. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med 2004; 229: 1136-1142
7. Munger KL, Zhang SM, O'Reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60-65
8. Ardizzone S, Cassinotti A, Bevilacqua M et al. Vitamin D and inflammatory bowel disease. Vitam Horm 2011; 86: 367-377
9. Pappa HM, Gordon CM, Saslowsky TM et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 2006; 118: 1950-1961
10. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med 2000; 223: 230-233
11. Provvedini DM, Tsoukas CD, Deftos LJ et al. 1,25-Dihydroxyvitamin D3 receptors in human leukocytes. Science 1983; 221: 1181-1183
12. Cantorna MT, Munsick C, Bemiss C et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648-2652
13. Froicu M, Weaver V, Wynn TA et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003; 17: 2386-2392
14. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol 2007; 8: 5
15. Miheller P, Muzes G, Hritz I et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009; 15: 1656-1662
16. Jorgensen SP, Agnholt J, Glerup H et al. Clinical trial: vitamin D3 treatment in Crohn's disease-a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010; 32: 377-383
17. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444
18. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-1608
19. Irvine EJ, Feagan B, Rochon J et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-296
20. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009; 24: 1252-1257
21. Sandborn WJ, Colombel JF, Schreiber S et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011; 17: 141-151
22. Loftus EV, Feagan BG, Colombel JF et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008; 103: 3132-3141
23. Sostegni R, Daperno M, Scaglione N et al. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003; 17(Suppl 2): 11-17
24. Di Sabatino A, Ciccocioppo R, Armellini E et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis 2004; 10: 573-577